Bionomics Limited Presents BNC105 Phase 2 Renal Cancer Trial Biomarker Data

Bionomics Limited today presented new important data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the European Society for Medical Oncology congress in Madrid, Spain. The data, presented by Dr Sumanta Pal, of the City of Hope Comprehensive Cancer Center in Duarte, CA, USA, emphasizes the plasma biomarker profile associated with favourable outcomes for patients treated with BNC105.

http://ift.tt/1nAEgKa